Samarium

An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.

Networked: 62 relevant articles (5 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Anderson, Pete: 5 articles (05/2008 - 08/2006)
2.	Aragon-Ching, Jeanny B: 2 articles (01/2016 - 01/2013)
3.	El-Amm, Joelle: 2 articles (01/2016 - 01/2013)
4.	Sartor, Oliver: 2 articles (02/2007 - 01/2004)
5.	Anderson, Peter M: 2 articles (08/2006 - 10/2005)
6.	Erlandson, Linda: 2 articles (08/2006 - 10/2005)
7.	Rodriguez, Vilmarie: 2 articles (08/2006 - 10/2005)
8.	Wiseman, Gregory A: 2 articles (08/2006 - 10/2005)
9.	Kikuta, Koki: 1 article (01/2022)
10.	Kume, Shinji: 1 article (01/2022)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 02/01/2007 - "Samarium Sm 153 lexidronam (Sm-153) is an effective and well-tolerated treatment for painful bone metastases. " 11/01/2009 - "Phase I trial of vertebral intracavitary cement and samarium (VICS): novel technique for treatment of painful vertebral metastasis." 10/01/2011 - "Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases." 08/01/2009 - "In this first report, we describe our experience of use of Samarium EDTMP in conjunction with biphosphonates in a haemodialysis patient for treatment of painful bone metastasis. " 09/01/2006 - "Samarium-EDTMP showed to be a safe and effective alternative for palliative treatment of bone metastases. "
2.	Pain (Aches) 10/01/2014 - "Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result." 04/01/2012 - "In diffuse bone pain radionuclids (such as samarium) can be beneficial. " 03/01/2007 - "Of the patients, 15.4% were not in pain at rest or on movement at baseline and continued to be free of pain 4 weeks after the administration of samarium. " 06/15/2000 - "Systemic metabolic radiotherapy with samarium 153 lexidronam appears to be a safe and efficacious method for treating patients with bone pain. " 06/15/2007 - "Results suggest that samarium Sm 153 lexidronam may be useful in the palliation of pain in dogs with primary bone tumors that are not candidates for curative-intent treatment."
3.	Neoplasms (Cancer) 06/15/2007 - "Of the 32 dogs with appendicular tumors, 20 (63%) had an improvement in the severity of lameness 2 weeks after administration of the first dose of radioactive samarium, 8 (25%) had no change in the severity of lameness, and 4 (12%) had a worsening. " 06/01/2012 - "To evaluate samarium Sm 153 lexidronam ((153)Sm-EDTMP) as a treatment option for dogs with bony tumors of the skull. " 06/01/2012 - "Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006)." 06/15/2007 - "To evaluate survival times and palliative effects associated with the use of samarium Sm 153 lexidronam in dogs with primary bone tumors. " 06/15/2007 - "Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005)."
4.	Prostatic Neoplasms (Prostate Cancer) 09/01/2000 - "Successful use of Samarium 153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer." 06/01/2005 - "To evaluate the cost-effectiveness of samarium [153Sm-EDTMP] (Quadramet) compared to conventional therapy in the treatment of pain in patients with prostate cancer and bone metastases. " 03/01/2009 - "This study assessed whether baseline and short-term patient-reported quality of life (QOL) differs in patients with symptomatic metastatic prostate cancer undergoing palliative management using opioids, nonsteroidal anti-inflammatory agents (NSAIDs), (89)strontium chloride ((89)Sr), and samarium-lexidronam ((153)Sm). "
5.	Multiple Myeloma 09/01/2004 - "153 Samarium-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma." 02/01/2009 - "A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma."

Related Drugs and Biologics

1.	Strontium
2.	Radiopharmaceuticals
3.	phosphonic acid
4.	Chlorides
5.	Radium-223
6.	Silicon Dioxide (Silica)
7.	Oxalates
8.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
9.	Opioid Analgesics (Opioids)
10.	Bortezomib (Velcade)

Related Therapies and Procedures

1.	Therapeutics
2.	Palliative Care (Palliative Therapy)
3.	Intravenous Administration
4.	Radiotherapy
5.	Drug Therapy (Chemotherapy)